(-0.13%) 5 140.25 points
(-0.11%) 38 515 points
(-0.06%) 17 894 points
(-0.29%) $82.39
(1.67%) $2.06
(-0.89%) $2 336.60
(-1.92%) $27.13
(-0.53%) $956.40
(0.22%) $0.934
(0.49%) $11.04
(0.20%) $0.798
(-0.09%) $93.21
2 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 5.42%
-0.50% $ 44.02
@ $45.58
Wydano: 14 vas. 2024 @ 22:47
Zwrot: -3.41%
Poprzedni sygnał: vas. 14 - 16:30
Poprzedni sygnał:
Zwrot: 2.09 %
Live Chart Being Loaded With Signals
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally...
Stats | |
---|---|
Dzisiejszy wolumen | 552 586 |
Średni wolumen | 696 204 |
Kapitalizacja rynkowa | 3.62B |
EPS | $0 ( 2024-02-15 ) |
Następna data zysków | ( $-1.730 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -5.34 |
ATR14 | $0.0330 (0.07%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-18 | Crombez Eric | Sell | 142 | Common Stock |
2024-04-16 | Huizenga Theodore Alan | Sell | 14 | Common Stock |
2024-03-11 | Kassberg Thomas Richard | Sell | 11 509 | Common Stock |
2024-03-07 | Fust Matthew K | Sell | 2 550 | Common Stock |
2024-03-07 | Fust Matthew K | Sell | 2 145 | Common Stock |
INSIDER POWER |
---|
45.65 |
Last 99 transactions |
Buy: 915 632 | Sell: 371 334 |
Wolumen Korelacja
Ultragenyx Pharmaceutical Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
GAINL | 0.862 |
ITMR | 0.852 |
DVCR | 0.847 |
AVEO | 0.845 |
ISNS | 0.842 |
VLYPP | 0.831 |
CHMA | 0.825 |
OPNT | 0.825 |
SUMR | 0.813 |
EDUT | 0.813 |
10 Najbardziej negatywne korelacje | |
---|---|
SHSP | -0.9 |
BOCH | -0.891 |
XFOR | -0.833 |
GRCL | -0.833 |
ENPH | -0.827 |
RDHL | -0.82 |
THTX | -0.819 |
PTPI | -0.805 |
QTEK | -0.801 |
BLU | -0.801 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Ultragenyx Pharmaceutical Korelacja - Waluta/Towar
Ultragenyx Pharmaceutical Finanse
Annual | 2023 |
Przychody: | $434.25M |
Zysk brutto: | $389.04M (89.59 %) |
EPS: | $-8.25 |
FY | 2023 |
Przychody: | $434.25M |
Zysk brutto: | $389.04M (89.59 %) |
EPS: | $-8.25 |
FY | 2022 |
Przychody: | $363.33M |
Zysk brutto: | $335.01M (92.21 %) |
EPS: | $-10.12 |
FY | 2021 |
Przychody: | $351.41M |
Zysk brutto: | $335.40M (95.44 %) |
EPS: | $-6.70 |
Financial Reports:
No articles found.
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej